by ramysaleh.ca | Feb 27, 2025 | Media
Dr. Ramy Saleh joins Dr. Neeraj Agarwal to highlight Actinium-225-PSMA-62, a novel radioligand therapy showing promising efficacy with fewer side effects, offering hope beyond Lutetium-177.
by ramysaleh.ca | Feb 15, 2025 | Media
Dr. Ramy Saleh presents the ACCEL phase Ia/Ib/II clinical trial—investigating the safety, tolerability, efficacy, and dosimetry of Actinium-225-PSMA-62 in men with oligometastatic hormone-sensitive and metastatic castration-resistant prostate cancer.
